Hunan Zhaotai Medical Group has formed a cancer treatment JV with New Zealand’s Malaghan Institute, which will conduct clinical trials on Zhaotai’s CAR-T cancer drug portfolio in New Zealand. Zhaotai has already conducted clinical trials of the drugs in China, and Malaghan’s tests in the “western regulatory environment” of New Zealand will serve as a bridge to other ex-China markets. New Zealand officials said the trials will speed up approvals of the new immunotherapies in New Zealand and draw additional foreign R&D investment to the nation.
